POZEN Inc. (NASDAQ:POZN) Is POZEN Inc. (NASDAQ:POZN) a buy, sell, or hold? The best stock pickers are becoming less confident.

POZEN Inc. (NASDAQ:POZN) a pharmaceutical company that develops products for the treatment of acute and chronic pain, and pain related conditions in the United States closed down in its previous session (-4.49%) on 711,968 shares traded after POZEN ...

POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it plans to release first quarter 2013 results on May 8, 2013, before the market opens.

Actual vs. Wall St. Expectations: POZEN, Inc. reported adjusted EPS loss of $0.19 per share. By that measure, the company missed the mean analyst estimate of $-0.19.

... NWSA NEWS CORP-A 48,488,208 40,490,393 19.8 MTSN MATTSON TECH 1,759,502 1,470,436 19.7 ALOG ANALOGIC CORP 589,764 493,201 19.6 POZN POZEN INC 2,032,085 1,699,902 19.5 IBKR INTERACTIVE BROK 718,495 603,019 19.1 SONC ...

POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the first quarter ended March 31, 2013.

3:12 p.m. CDT, May 8, 2013. The following corporation was updated in the Illinois Secretary of State's Department of Business Services database of corporate activity March 5: Jeffrey Pozen Advisory Inc. registered as an active domestic corporation March 5.

... -0.8 POZEN INC Q1 DRUGS USD -0.19 -0.19 -0.01 1.4 1.4 0.0 PREFERRED APARTMENT COMM Q1 INVESTMENTS USD -0.33 -0.79 -0.46 5.6 6.0 0.4 PRIMERO MINING CORP Q1 PRECIOUS METALS USD 0.06 0.10 0.04 42.9 46.3 3.5 QUEBECOR INC ...

OF YEAR AGO ESTIMATE EST EPS 07 May AMC Q1 2013 ACADIA Pharmaceuticals -0.08 9 -0.12 07 May BMO Q2 2013 AECOM 0.51 9 0.43 07 May BMO Q1 2013 Almost Family Inc 0.43 6 0.53 07 May BMO Q1 2013 Akorn, Inc. 0.14 5 0.13 07 May BMO Q1 ..... Inc. 0.29 5 0.26 ...

For the first quarter of 2013, POZEN Inc. (NASDAQ:POZN) reported revenue of $1.4 million compared to total revenue of $1.3 million for the first quarter of 2012, revenue for both quarters was royalty for sales of VIMOVO.